Kornimate/medical-research-clean huggingface dataset:
a risk scores for predicting prevalence of diabetes in the lao population

Conditions: Undiagnosed Diabetes

Summary: this was a cross-sectional investigation conducted from december 2015 to july 2017, in 15 selected rural villages of 2 districts of vientiane municipality, lao pdr. target population was interested people, both men and women of age range between 30 to 70 years, living in the selected community. someone diagnosed with diabetes and/or using any anti-diabetic drug was excluded. the study protocol initiated with the interview on demographic and behavior information with each participant, followed by physical exam and blood pressure measurement. fasting glucose were measured.

all participants were invited to meet with the researcher. demographic data comprises of age, gender, family history of diabetes including parents and sibling, female with history of having baby weighing more than 4 kg, gestational diabetes, and history or current of dyslipidemia (triglycerides \>150 mg/dl, ldl-c ≥ 100 mg/dl, hdl-c \< 35 mg/dl), and behavior data were smoking habit, physical inactivity (less than 150 min/week or 3 day/week) were collected by interview. after that each participant was appointed for blood pressure measurement. body mass index was computed from body weight (kg) divided by body height (m2) using the weight and height scale. waist circumference was measured at the midpoint between the superior border of iliac crest and the lowest rib using measuring tape with the subject in the position of standing relax and in underclothes hip circumference is measured at the level of maximal gluteal protrusion blood pressure (bp) value was done with the participants, after 5 minutes relaxing, sitting up right with their upper arm positioned at heart level and measured by omron blood pressure monitor. fasting plasma glucose was utilized to identify an individual who is normal, has either pre-diabetes or undiagnosed diabetes. venous blood samples were collected 5 ml from antecubital vein into the test tube

Eligibility criteria:
inclusion criteria: * of age range between 30 to 70 years, living in the selected community. exclusion criteria: * diagnosed with diabetes and/or using any anti-diabetic drug
detection of egfr mutations in the blood of patients with non-small cell lung cancer: a feasibility study

Conditions: Non Small Cell Lung Cancer

Summary: the overall objective of the study is to assess the feasibility of the use of blood for the detection of egfr mutations in patients with non-small cell lung cancer (nsclc) specific aims are: 1. to assess the use of immuno-separation techniques to enrich the tumor cell population in the blood of nsclc patients. 2. to assess the use of denaturing high performance liquid chromatography (dhplc) assay for the detection of egfr mutations in the blood of nsclc patients.

the oral tyrosine kinase (tk) inhibitors of epidermal growth factor receptor (egfr), gefitinib and erlotinib, have produced dramatic responses, encouraging response rates and possibly improved survival in a subset of nsclc patients. evidence suggests that somatic egfr mutations in the tumor are at present the single most reliable biological marker of predicting response to egfr tk inhibitors. in addition, these mutations may be an early event in the pathogenesis of nsclc in a subset of patients. unfortunately, the technology of egfr mutations sequencing incurs high costs and requires sufficient tissue, which is often a problem in nsclc. we hypothesize that egfr mutations can be detected in the blood and propose a study to determine the feasibility of detecting egfr mutations in the blood of nsclc patients. we will approach newly diagnosed nsclc patients as well as patients who are known to be responding to the oral tk inhibitors. we will perform egfr mutations on the tumors. for the blood, we will use new immuno-separation techniques to isolate tumor cells and perform denaturing high performance liquid chromatography to detect egfr mutations. if we prove that it is feasible to detect the mutations in the blood, we will follow up with a validation study. many applications can result if our hypothesis holds true: 1) it will be proof of principle that our technique can effectively isolate and detect somatic mutations in circulating tumor cells, 2) it will be a simple way to overcome the problem of insufficient tumor samples, 3) it can be used for early detection of lung cancer if egfr mutations proves to be important in pathogenesis in a subset of patients and 4) the technology can be extended to detect new mutations in patients who become resistant to oral tk inhibitors which can lead to new targeted therapies.

Eligibility criteria:
patients with non small cell lung cancer.
radiation-free technique for evaluating renal scarring (rafters)

Conditions: Vesico-Ureteral Reflux

Summary: in this research study the investigators want to study a safe, radiation-free technique known as contrast-enhanced ultrasound that may improve the ability to diagnose or evaluate renal scarring compared to regular ultrasound. this technique requires injection into a vein of a small amount of contrast material called lumason. contrast material is a type of dye that helps the investigators image the structures in the body more clearly. if this technique is successful, the need for dmsa studies may be avoided to diagnose or evaluate kidney scarring. dmsa is a more expensive test, causes radiation exposure, may require sedation and/or injection of contrast agents with the potential to cause allergic reactions.


Eligibility criteria:
inclusion criteria: * patients older than or equal to 6 months and less than or equal to 35 years old and scheduled for boston children's hospital (bch) dmsa scan to evaluate renal function and/or renal scarring exclusion criteria: * patients with significant congenital renal anatomical abnormalities including horseshoe kidney, kidney malrotation, and multicystic dysplastic kidney (mcdk). patients with severe cardio-pulmonary diseases will also be excluded.
treatment of overweight in children on distance

Conditions: Overweight

Summary: the present study is a public health project with the aim to treat overweight in children 9-11 years of age. after the first consultation the children are randomized to either continue the treatment at the child obesity clinic, child department or to have the following 2-3 consultations on distance with lync. last visit for all children is on the child obesity clinic after approximately 12 months. follow up after at least 1 years will be performed.

this superiority study is a randomized trial with two independent treatment arms. the target for the enrollment is 50% in each of the two treatment groups. with 60 patients in each group, the study has 80% statistical power at 5% significance level to detect an average difference between the treatment groups in the intra-individual change in the bmi z-score that is 0.51 x the standard deviation in the intra-individual change. previous data from the investigators own group suggest that a reasonable estimate of the standard deviation in the intra-individual change in the bmi z-score following intervention is 0.42. thus, the study has 80% statistical power at 5% significance level to detect a difference in the intra-individual change in the bmi z-score that is 0.51 x 0.42 = 0.21 on average. the study will with the present funding end its follow up in june 2017.

Eligibility criteria:
inclusion criteria: - children with overweight and not obese according to the definitions developed by cole et al (4). it implies that we include children with the following age specific bmi inclusion criteria * 9 years = age \< 9 years, 6 months and 19,0\< bmi\<23,0 * 9 years, 6 months =\> age \< 10 years and 19,5 \<bmi\<23,5 * 10 years = age \< 10 years, 6 months and 20,0\<bmi\<24,0 * 10 years, 6 months=\>age\< 11 years and 20,5\<bmi\<24,5 * 11 years = age \< 11 years, 6 months and 21,0\<bmi\<25,5 * 11 years, 6 months =\>age\<12 years and 21,5\<bmi\<25,5 exclusion criteria: * children and his/her parents not able to communicate in swedish. * children with monogenic obesity * present less than 80% at school in the latest school year. * no foster care for the child or his/her brothers or sisters

Keywords: overweight children treatment prevention lifestyle intervention
effects of soft tissue mobilization technique and piriformis muscle stretching among patients having piriformis syndrome

Conditions: Piriformis Syndrome

Summary: it is a randomized control trail in which soft tissue mobilization and piriformis stretching will be compared and study duration will be of five months

piriformis syndrome is one of the misdiagnosed syndromes and there is no evidence available for the proper diagnosis of this syndrome. several interventions have been adopted in the clinical setting for improvement of piriformis syndrome including therapeutic ultrasound, myofascial release, stretching, dry needling, strengthening exercises of hip muscles and activity modification. there are several treatments available for this syndrome but no comparison studies have been reported yet on soft tissue mobilization and piriformis muscle stretching. the purpose for conducting this research is to assist in establishing the effectiveness of soft tissue mobilization technique and piriformis muscle stretching in piriformis syndrome by comparison between two abovementioned treatments

Eligibility criteria:
inclusion criteria: * males and females with age between 25 and 45 years * patients with positive piriformis test * pain at least 3 according to numeric pain rating scale (nprs) exclusion criteria: * history of hip pain due to any diagnosed hip pathology * leg length discrepancy * past history of spinal surgery * spinal tuberculosis * rheumatoid disease,
vistacare® in the treatment of wounds of the lower extremity

Conditions: Wound Heal

Summary: assessment of the safety and performance of the vistacare® medical device in current medical practice in the treatment of acute and chronic lower limb wounds.

the study is an open-label, prospective, multicenter, post-ce mark (european conformity assessment indicating marketing approval in europe) study to assess the safety and performance of the vistacare® device in the treatment of wounds. the duration of patient follow-up is up to 30 days, with intermediate visits at 3, 7, 15 and 30 days following initiation of treatment with the device. up to 30 patients will be recruited in the trial. assessments will include clinical status, wound status, standardized photography, tcpo2 (trans-cutaneous oxygen pressure assessment) in a study sub-population, visual analogy scales to assess pain and comfort and adverse events monitoring.

Eligibility criteria:
inclusion criteria: * male or female consenting and able patients aged 18 or more affiliated to social security * presenting with acute or chronic traumatic or surgical lower limb wounds (excluding tumoral excision) * presenting with no intercurrent pathology which in the opinion of the investigator may interfere with the capacity for wound healing * patients whose wound is compatible in terms of location with vistacare treatment * patient whose wound has a minimal surface of 10 cm2 * patient whose wound does not need surgical peterson after inclusion (if needed should be performed prior to inclusion) exclusion criteria: * female patients pregnant, lactating, or of childbearing age and not using adequate contraception (pregnancy test mandatory) * patients incapable of making an informed decision about participation * patients presenting a condition that interferes with adequate wound healing capacity (uncontrolled diabetes, heavy smokers, auto-immune disease) * concurrent treatment or treatment within one month prior to inclusion with local or systemic corticosteroids, immunosuppresseurs, chemotherapy or radiotherapy * wound location incompatible with vistacare * general infection signs at the time of inclusion (fever, lymphangitis, pus ...) * patients presenting with important uncontrolled hemorrhage at the time of inclusion * patients previously recruited into this trial or any other trial within 1 month, or currently in the exclusion timeframe of another trial * patients with a wound surface less than 10 cm2 * patient with a would previously treated with hyperbaric chamber * legally incapacitated, under guardianship or psychiatric patients * emergency condition prohibiting adequate patient consent prior to inclusion

Keywords: wound vistacare wound healing controlled atmosphere
heart valve prosthesis-patient mismatch

Conditions: Heart Valve Diseases

Summary: the purpose of this study is to determine the frequency of prosthesis-patient mismatch after mitral valve replacement and its effect on clinical outcomes.

mitral valve replacement (mvr) is associated with higher short and long term mortality than aortic valve replacement or mitral valve repair. the suboptimal results of mvr underline the importance of identifying and preventing prosthesis- patient mismatch. the effective orifice area (eoa) of prosthetic valves used for mvr is often too small in relation to body size, thus causing a mismatch between valve eoa and transvalvular flow. as a consequence, normally functioning mitral prostheses often have relatively high gradients that are similar to those found in patients with mild to moderate mitral stenosis. residual pressure gradients across mitral prostheses delay the regression of left atrial and pulmonary arterial hypertension. pulmonary hypertension may cause rightsided failure and is an important risk factor for morbidity and mortality in patients with cardiovascular diseases. however data about the frequency of prosthesis-patient mismatch after mitral valve replacement and its effect on clinical outcome is inconclusive. predetermined outcomes will be evaluated in the clinical course of this condition.

Eligibility criteria:
inclusion criteria: * patients \> 18 years with a clinical condition of mitral valve prosthesis exclusion criteria: * evidence of prosthesis valve dysfunction (dehisence, endocarditis or thrombus of prosthetic mitral valve) * concomitant aortic valve prosthesis and tricuspid valve prosthesis * presence of \> +2 aortic valve regurgitation and/or mild aortic stenosis * prosthetic mitral valve replacement operation \< 6 months * left ventricular ejection fraction \< 50% * chronic obstructive pulmonary disease * concomitant hypertrophic cardiomyopathy, atrial septal defect * patients with poor ehocardiographic window

Keywords: heart valve prosthesis
a non-interventional pilot study to explore the role of gut flora in obsessive-compulsive disorder

Conditions: Obsessive-Compulsive Disorder

Summary: this study seeks to correlate microbiome sequencing data with information provided by patients and their medical records.

the goal of this research study is to better understand how the genetic information in subject's microbiome correlates to infection with obsessive-compulsive disorder.

Eligibility criteria:
inclusion criteria: 1. signed informed consent, demonstrating that the patient understands the procedures required for the study and the purpose of the study a. may be signed by parent or legal guardian in the case of minor or adult unable to provide consent 2. male or female of all ages 3. oci greater than or equal to 21 exclusion criteria: 1. refusal to sign informed consent form 2. history of bariatric surgery, total colectomy with ileorectal anastomosis or proctocolectomy. 3. postoperative stoma, ostomy, or ileoanal pouch 4. participation in any experimental drug protocol within the past 12 weeks 5. treatment with total parenteral nutrition
persistent readiness through early prediction immunization study

Conditions: Inflammatory Response

Summary: this study will enroll volunteers in an open-format (outside hospital) setting, to complete novel data collection/analysis of biomarkers, facial images, and audio-recording to establish an optimal set of parameters to predict emergent cases of infection via an early warning score, along with actionable personalized information.

the objective of the study is to collect data from participants for a period of 4 weeks. these data will be used for developing and testing an algorithm for early detection of infection. at the end of week two, subjects will receive an immunization in a double-blind randomized placebo-controlled fashion. vaccines to be administered will be pneumococcal (ppsv23), typhoid (inactivated), or saline. administration of these vaccines often cause mild 'infection-like' inflammation response. pneumococcal infection causes pneumonia and can lead to sepsis and the ppsv23 vaccination will induce mild symptoms related to the immune system activation including local reaction in 50% of the cases and fever and malaise in 1% of the cases. typhoid fever is caused by salmonella typhi bacteria and its effects can range from gastrointestinal symptoms to sepsis. injectable typhoid vaccine (inactivated) side effects will induce mild symptoms related to the immune system activation and can include local reaction in 6% of the cases and fever, malaise, headache and sometimes diarrhea in 1% of the cases.

Eligibility criteria:
inclusion criteria: * ages 18-40 (inclusive) * subject is judged to be in satisfactory health based on medical history, physical examination * ability to walk, sit down and stand up independently * willingness and ability to comply with the protocol * ownership and use of smartphone * ownership and use of laptop exclusion criteria: * subject has planned elective surgery requiring 2 or more days of hospitalization during the entire study * active dependence of alcohol or drugs (self-reported) * known allergy to any of the following: * components of the vaccine/placebo * diagnosed and active treatment of chronic disease: * diabetes (type 1 or 2) * active malignancy * heart disease * kidney disease * liver disease * hiv/aids * hepatitis a, b, or c * asthma (moderate to severe) * (possible/desire to be) pregnancy (confirmed via urine pregnancy test) * subject is currently enrolled in a study with an investigational compound or device * subject has already received the pneumococcal (ppsv23) vaccine * subject has already received the typhoid (inactivated) vaccine * subject has received any other investigational vaccination within 4 weeks of enrollment * any other condition that interfere with the definition 'healthy" based on self-report and according to the pi/study physician's judgement based on medical history, use of medication, and physical exam.

Keywords: commercial off the shelf wearable devices large-scale machine learning biomarkers early warning of infection predictive model of illness severity predictive model of recovery
evaluation of an intervention program for the prevention of anemia

Conditions: Anemia

Summary: the purpose of the study is to determine whether improvement in the accessibility to iron supplement will decrease anemia rates in infants.

iron deficiency anemia is the most common type of anemia in infants, children and women of reproductive age. the most frequent cause of iron deficiency in infants at 6 months of life is poor nutrition during a period of rapid growth and a diet lacking in iron rich foods. children who suffered from anemia in infancy demonstrated slower cognitive development, were low achievers in school and had a high rate of behavioral disturbances. the ministry of health implements a primary prevention program for anemia. if by making iron supplements more accessible would increase parental compliance in acquisition of the iron supplement and subsequently reduce the rate of iron deficiency anemia, the result would be the immediate application of the finding. it is possible to implement a program whereby the supplement will be directly available at the family health centers for purchase by the parent.

Eligibility criteria:
inclusion criteria: * infant who visit family health centers

Keywords: anemia iron supplement
odyssey outcomes: evaluation of cardiovascular outcomes after an acute coronary syndrome during treatment with alirocumab

Conditions: Atherosclerotic Cardiovascular Disease

Summary: primary objective: to compare the effect of alirocumab with placebo on the occurrence of cardiovascular (cv) events (composite endpoint of coronary heart disease (chd) death, non-fatal myocardial infarction (mi), fatal and non-fatal ischemic stroke, unstable angina (ua) requiring hospitalization) in participants who experienced an acute coronary syndrome (acs) event 4 to 52 weeks prior to randomization and were treated with evidence-based medical and dietary management of dyslipidemia. secondary objectives: * to evaluate the effect of alirocumab on secondary endpoints (any chd event , major chd event, any cv event, composite of all cause mortality/non-fatal mi/non-fatal ischemic stroke, chd deaths, cv deaths, all cause mortality). * to evaluate the safety and tolerability of alirocumab. * to evaluate the effect of alirocumab on lipid parameters.

18924 number of participants aged \>= 40 years old were randomized in the study.

Eligibility criteria:
inclusion criteria : recently (\< 52 weeks) hospitalized for acs. exclusion criteria: * age \< 40 years. * acs event occurring more than 52 weeks prior to randomization visit. * ldl-c likely to be \<70 mg/dl (\<1.81 mmo/l), and apolipoprotein b (apob) \<80 mg/dl (\<0.8 g/l), and non - high-density lipoprotein cholesterol (hdl-c) \<100 mg/dl (\<2.59 mmol/l) with evidence-based medical and dietary management of dyslipidemia. the above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
toripalimab combined with donafenib in the treatment of advanced hepatocellular carcinoma

Conditions: Advanced Hepatocellular Carcinoma

Summary: this study is an open, multi-center phase i/ii clinical study.

it will explore the tolerability (phase i) and effectiveness (phase ii) of the donafenib tosilate tablets combined with toripalimab injection in patients with advanced hcc. the study is conducted in two phases, the first phase is the dose exploration phase (phase i), and the second phase is the dose expansion phase (phase ii).

Eligibility criteria:
inclusion criteria: * patients with locally advanced or metastatic hcc who are not suitable for surgical resection, who are clinically diagnosed or confirmed by histopathology and/or cytology according to the "standards for the diagnosis and treatment of primary liver cancer" (2017); * at least one measurable lesion (according to recist v1.1); * ecog performance status score of 0 or 1; * life expectancy ≥ 12 weeks； * have not received systemic therapy (systemic chemotherapy and/or molecular targeted therapy).if the patient has received adjuvant chemotherapy after local treatment, the chemotherapy needs to be over for more than 12 months, and disease progression or metastasis occurs； * fully understand this research and voluntarily sign the icf。 exclusion criteria: * patients with diffuse liver cancer, hepatic encephalopathy that is difficult to control, and liver cancer patients whose lesion size accounts for 70% or more of the entire liver. * patients with intrahepatic cholangiocarcinoma (icc) or hcc-icc mixed type； * tumor invades inferior vena cava vp4.

Keywords: hcc